Table 2. Biodistribution and... | American Society of Hematology

Table 2.

Biodistribution and Pharmacokinetics for¹³¹I-BC8 Antibody

Patient Group and Marrow Status	Marrow		Spleen		Liver
Patient Group and Marrow Status	Hr 0% ID/g	t½ (h)	Hr 0% ID/g	t½ (h)	Hr 0% ID/g	t½ (h)
All patients	0.028 ± 0.012	44.2 ± 14.7	0.060 ± 0.032	35.3 ± 10.3	0.013 ± 0.004	32.0 ± 8.4
AML/MDS	0.029 ± 0.014	46.7^* ± 15.8	0.061 ± 0.030	36.9^† ± 11.0	0.013 ± 0.004	33.3 ± 8.6
Remission	0.025 ± 0.008	35.5^‡ ± 6.5	0.042^2-153 ± 0.017	34.3 ± 12.3	0.013 ± 0.004	27.7^2-155 ± 5.5
Relapse/MDS	0.030 ± 0.015	51.4^‡ ± 16.3	0.070^2-153 ± 0.030	37.9 ± 10.6	0.013 ± 0.004	35.6^2-155 ± 8.7
ALL	0.024 ± 0.005	35.7^* ± 3.3	0.057 ± 0.040	30.2^† ± 4.7	0.013 ± 0.003	27.8 ± 6.5
Remission	0.026 ± 0.005	35.2 ± 1.8	0.072 ± 0.053	29.3 ± 31.1	0.013 ± 0.003	25.8 ± 5.7
Relapse	0.022 ± 0.003	36.3 ± 4.6	0.043 ± 0.014	31.1 ± 4.7	0.013 ± 0.003	29.9 ± 7.1

Patient Group and Marrow Status	Marrow		Spleen		Liver
Patient Group and Marrow Status	Hr 0% ID/g	t½ (h)	Hr 0% ID/g	t½ (h)	Hr 0% ID/g	t½ (h)
All patients	0.028 ± 0.012	44.2 ± 14.7	0.060 ± 0.032	35.3 ± 10.3	0.013 ± 0.004	32.0 ± 8.4
AML/MDS	0.029 ± 0.014	46.7^* ± 15.8	0.061 ± 0.030	36.9^† ± 11.0	0.013 ± 0.004	33.3 ± 8.6
Remission	0.025 ± 0.008	35.5^‡ ± 6.5	0.042^2-153 ± 0.017	34.3 ± 12.3	0.013 ± 0.004	27.7^2-155 ± 5.5
Relapse/MDS	0.030 ± 0.015	51.4^‡ ± 16.3	0.070^2-153 ± 0.030	37.9 ± 10.6	0.013 ± 0.004	35.6^2-155 ± 8.7
ALL	0.024 ± 0.005	35.7^* ± 3.3	0.057 ± 0.040	30.2^† ± 4.7	0.013 ± 0.003	27.8 ± 6.5
Remission	0.026 ± 0.005	35.2 ± 1.8	0.072 ± 0.053	29.3 ± 31.1	0.013 ± 0.003	25.8 ± 5.7
Relapse	0.022 ± 0.003	36.3 ± 4.6	0.043 ± 0.014	31.1 ± 4.7	0.013 ± 0.003	29.9 ± 7.1

Values are the means ± SD. % ID/g was estimated by extrapolation to time 0 for marrow.

P = .001 for difference between patients with AML/MDS and ALL.

P = .009 for difference between patients with AML/MDS and ALL.

P < .001 for difference between remission and relapse in patients with AML/MDS.

P = .01 for difference between remission and relapse in patients with AML/MDS.

P = .013 for difference between remission and relapse in patients with AML/MDS.